161 related articles for article (PubMed ID: 10640513)
1. Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.
Kohl C; Steinkellner M
Drug Metab Dispos; 2000 Feb; 28(2):161-8. PubMed ID: 10640513
[TBL] [Abstract][Full Text] [Related]
2. No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics.
Masche UP; Rentsch KM; von Felten A; Meier PJ; Fattinger KE
Eur J Clin Pharmacol; 1999 Jan; 54(11):865-8. PubMed ID: 10027662
[TBL] [Abstract][Full Text] [Related]
3. Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics.
Masche UP; Rentsch KM; von Felten A; Meier PJ; Fattinger KE
Eur J Clin Pharmacol; 1999 Jan; 54(11):857-64. PubMed ID: 10027661
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M
Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective interaction between piroxicam and acenocoumarol.
Bonnabry P; Desmeules J; Rudaz S; Leemann T; Veuthey JL; Dayer P
Br J Clin Pharmacol; 1996 Jun; 41(6):525-30. PubMed ID: 8799517
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.
Ravic M; Johnston A; Turner P
Postgrad Med J; 1990; 66 Suppl 4():S30-4. PubMed ID: 2126624
[TBL] [Abstract][Full Text] [Related]
7. Effect of the CYP2C9*3 allele on lornoxicam metabolism.
Liu YL; Zhang W; Tan ZR; Ouyang DS; Luo CH; Liu ZQ; Qiu Y; Chen Y; He YJ; Zhou G; Zhou HH
Clin Chim Acta; 2006 Feb; 364(1-2):287-91. PubMed ID: 16182270
[TBL] [Abstract][Full Text] [Related]
8. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam.
Bonnabry P; Leemann T; Dayer P
Eur J Clin Pharmacol; 1996; 49(4):305-8. PubMed ID: 8857077
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
Ufer M; Kammerer B; Kahlich R; Kirchheiner J; Yasar U; Brockmöller J; Rane A
Xenobiotica; 2004 Sep; 34(9):847-59. PubMed ID: 15742978
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance.
Takahashi H; Kashima T; Kimura S; Murata N; Takaba T; Iwade K; Abe T; Tainaka H; Yasumori T; Echizen aH
Drug Metab Dispos; 1999 Oct; 27(10):1179-86. PubMed ID: 10497145
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
Olkkola KT; Brunetto AV; Mattila MJ
Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
[TBL] [Abstract][Full Text] [Related]
12. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.
Iida I; Miyata A; Arai M; Hirota M; Akimoto M; Higuchi S; Kobayashi K; Chiba K
Drug Metab Dispos; 2004 Jan; 32(1):7-9. PubMed ID: 14709614
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam.
Skjodt NM; Davies NM
Clin Pharmacokinet; 1998 Jun; 34(6):421-8. PubMed ID: 9646006
[TBL] [Abstract][Full Text] [Related]
14. Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes.
Kammerer B; Kahlich R; Ufer M; Schenkel A; Laufer S; Gleiter CH
Anal Bioanal Chem; 2005 Nov; 383(6):909-17. PubMed ID: 16237546
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon.
Haustein KO
Semin Thromb Hemost; 1999; 25(1):5-11. PubMed ID: 10327214
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of lornoxicam in man.
Hitzenberger G; Radhofer-Welte S; Takacs F; Rosenow D
Postgrad Med J; 1990; 66 Suppl 4():S22-7. PubMed ID: 2284217
[TBL] [Abstract][Full Text] [Related]
17. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
[TBL] [Abstract][Full Text] [Related]
18. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
[TBL] [Abstract][Full Text] [Related]
19. [Determination of lornoxicam in human plasma by LC/MS/MS].
Zeng YL; Chen XY; Zhang YF; Zhong DF
Yao Xue Xue Bao; 2004 Feb; 39(2):132-5. PubMed ID: 15127622
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
Thijssen HH; Flinois JP; Beaune PH
Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
